secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001213900-23-010353
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity receives Nasdaq delisting notice over independent director/audit committee non-compliance
--------------------------------------------------------------------------------

- Nasdaq notified Allarity on Feb 8, 2023 that it fails Listing Rules 5605(b)(1)(A) and 5605(c)(4) after director Soren G. Jensen resigned from board and audit committee, effective Feb 4, 2023.
- No immediate effect on listing; common stock continues trading under ALLR on Nasdaq Global Market.
- Cure period: must comply by earlier of next annual shareholders' meeting or Feb 4, 2024; if annual meeting before Aug 3, 2023, compliance due by Aug 3, 2023.
- Company is seeking a new independent director who qualifies for audit committee membership to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/0001213900-23-010353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/ea173153-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-010353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer